KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Gains from Investment Securities (2019 - 2025)

Royalty Pharma's Gains from Investment Securities history spans 7 years, with the latest figure at -$13.8 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 399.24% year-over-year to -$13.8 million; the TTM value through Jun 2025 reached -$20.4 million, down 183.12%, while the annual FY2024 figure was -$2.0 million, 116.26% down from the prior year.
  • Gains from Investment Securities for Q2 2025 was -$13.8 million at Royalty Pharma, down from $13.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $24.5 million in Q2 2022 and bottomed at -$28.3 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $3.8 million (2022), against an average of $332800.0.
  • The largest annual shift saw Gains from Investment Securities tumbled 550.02% in 2021 before it soared 433.34% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$28.3 million in 2021, then surged by 186.34% to $24.5 million in 2022, then tumbled by 139.67% to -$9.7 million in 2023, then tumbled by 106.57% to -$20.0 million in 2024, then skyrocketed by 31.25% to -$13.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Gains from Investment Securities are -$13.8 million (Q2 2025), $13.4 million (Q1 2025), and -$20.0 million (Q3 2024).